SAN DIEGO, Jan. 3 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. , a biopharmaceutical company developing and commercializing recombinant human enzymes, today announced that it will present at the JPMorgan 25th Annual Healthcare Conference to be held at the Westin St. Francis Hotel in San Francisco on January 8-11, 2007.
Jonathan Lim, MD, Halozyme’s President and Chief Executive Officer, will present on Thursday, January 11, 2007 at 12:30 p.m. Pacific time (3:30 p.m. Eastern time) and will discuss the Company’s strategic initiatives, product pipeline and market opportunities.
Interested parties can access a live audio webcast and accompanying slide presentation via the Internet by visiting the Investor Relations section of the Company’s Web site at www.halozyme.com. An archived presentation will be available on the Web site for 30 days.
About Halozyme Therapeutics, Inc.
Halozyme is a biopharmaceutical company developing and commercializing recombinant human enzymes for the drug delivery, palliative care, oncology, and infertility markets. The company’s portfolio of products is based on intellectual property covering the family of human enzymes known as hyaluronidases. Halozyme’s recombinant human enzymes may replace current animal slaughterhouse-derived extracts that carry potential risks of animal pathogen transmission and immunogenicity. The company has received FDA approval for two products: Cumulase(R), the first and only recombinant human hyaluronidase for cumulus removal in the IVF process; and Hylenex for use as an adjuvant to increase the absorption and dispersion of other injected drugs. The versatility of the first enzyme, rHuPH20, enables Halozyme to develop the product as a medical device, drug enhancement agent, and therapeutic drug.
Halozyme Contact Investor Relations Contact David A. Ramsay Zachary Bryant Chief Financial Officer Lippert/Heilshorn & Associates (858) 794-8889 (310) 691-7100 dramsay@halozyme.comzbryant@lhai.com
Halozyme Therapeutics, Inc.
CONTACT: David A. Ramsay, Chief Financial Officer of Halozyme,+1-858-794-8889, dramsay@halozyme.com; or Investor Relations, ZacharyBryant of Lippert/Heilshorn & Associates, +1-310-691-7100,zbryant@lhai.com, for Halozyme
Web site: http://www.halozyme.com/
